glp-1 based therapeutics summit 2nd GLP-1-Based 2025 • Biopharma Asia GLP-1-Based Therapeutics Summit

There is no current evidence that GLP-1 medications cause this kind of permanent nerve damage [1] [2]

[DOI] [PubMed] [Google Scholar] [66].Watson E, Jonker DM, Jacobsen LV, Ingwersen SH, Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide, Journal of clinical pharmacology, 50 (2010) 886894

PMID: 41310257

If a patient depends only on appetite suppression, maintenance may become difficult when appetite changes or medication access changes

Brain Fog, Burnout, and Low Energy: Why Injectable NAD+ Is Getting So Much Attention Feeling foggy, drained, or burned out

GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models